Valuation: Seres Therapeutics, Inc.

Market Cap 75.44M 66.05M 60.98M 56.94M 107M 7.13B 110M 734M 283M 3.52B 283M 277M 12.22B P/E 2026 *
-1.04x
P/E 2027 * -1.18x
Enterprise Value 75.44M 66.05M 60.98M 56.94M 107M 7.13B 110M 734M 283M 3.52B 283M 277M 12.22B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 211x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+10.03%
1 week+18.03%
Current month+6.42%
1 month+6.42%
3 months-13.44%
6 months-47.79%
Current year-47.65%
1 week 6.52
Extreme 6.52
7.8
1 month 5.31
Extreme 5.31
7.99
Current year 5.31
Extreme 5.31
16.42
1 year 5.31
Extreme 5.31
29.98
3 years 5.31
Extreme 5.31
105.8
5 years 5.31
Extreme 5.31
477.8
10 years 5.31
Extreme 5.31
770
Manager TitleAgeSince
Chief Executive Officer 70 2026-03-01
Chief Executive Officer 58 2025-07-31
President 51 2026-03-01
Director TitleAgeSince
Chairman 70 2026-03-01
Director/Board Member 50 2019-01-14
Director/Board Member 80 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
May. 17Sell

General Counsel

-79 0.0008%
May. 17Sell

Chairperson

-77 0.0008%
May. 17Sell

Chief Operating Officer

-59 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+10.03%+18.03%-14.40%-91.70% 75.44M
+3.51%-0.12%+72.84%+128.47% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+7.65%+7.64%+39.85%-28.72% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +5.05%+7.37%+60.40%+131.88% 22.66B
Weighted average by Cap. +4.59%+7.70%+66.90%+143.18%

Financials

2026 *2027 *
Net sales 12.86M 11.26M 10.39M 9.71M 18.27M 1.22B 18.69M 125M 48.28M 600M 48.29M 47.23M 2.08B 358K 313K 289K 270K 509K 33.85M 520K 3.48M 1.34M 16.7M 1.34M 1.31M 57.97M
Net income -70.97M -62.14M -57.37M -53.57M -101M -6.71B -103M -690M -266M -3.31B -267M -261M -11.49B -99.82M -87.41M -80.69M -75.35M -142M -9.44B -145M -971M -375M -4.66B -375M -367M -16.17B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26-06-29 $7.790 +10.03% 131,503
26-06-26 $7.080 +3.43% 301,492
26-06-25 $6.845 +0.51% 119,931
26-06-24 $6.810 -3.40% 48,870
26-06-23 $7.050 +6.82% 75,176
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.790USD
Average target price
17.00USD
Spread / Average Target
+118.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock